Precision Biosciences, Inc. · NASDAQ:DTIL
Precision Biosciences — Investor Presentation (January 2026)
33 slides from Precision Biosciences's investor presentation, January 2026
Slide 1: Corporate Deck
PRECISION BIOSCIENCES Corporate Deck January 2026 my
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, as may any related presentations, within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-
Slide 3: ARCUS Gene Editing Platform Now Clinically Validated with Two Lead Programs
ARCUS Gene Editing Platform Now Clinically Validated with Two Lead Programs Clinical Data Timing 〉 First-in-Class mechanism targeting cccDNA elimination PBGENE-HBV 〉 Active drug across doses and HBsAg Levels with durable responses in 7 of 9 2026 Phase 1/2a Program for patients reported Chronic Hepat
Slide 4: Simplicity: ARCUS is the Only Single Protein Component Gene Editor
Simplicity: ARCUS is the Only Single Protein Component Gene Editor Single protein with a DNA recognition motif and catalytic ARCUS activity all in one; no guide RNA required Editing outcome not dependent on simultaneous delivery of multiple components leading to higher efficiency Single component re
Slide 5: Dr. MF Yuen Presented Late Breaking Oral Presentation on PBGENE-HBV at AASLD
Dr. MF Yuen Presented Late Breaking Oral Presentation on PBGENE-HBV at AASLD Phase 1 datasets rarely receive late breaking oral presentations* MF Yuen, MD, PhD Late-Breaking Abstract Presentation Chair Professor of Gastroenterology and Hepatology, Li Shu Fan Medical Foundation Professor in Medicine,
Slide 6: PBGENE-DMD: Novel Candidate with Clear Advantages Over Existing Treatments
PBGENE-DMD: Novel Candidate with Clear Advantages Over Existing Treatments Ideal therapy Microdystrophin Exon Skipping PBGENE-DMD would have: Gene Therapies Therapies Target Product Profile Improved muscle function over time Long-term durable benefit Broadly applicable to patients Corrects human dys
Slide 7: The First and Only Gene Editor for Chronic Hepatitis B: PBGENE-HBV
The First and Only Gene Editor for Chronic Hepatitis B: Clinical Data to Date Demonstrates Repeat Dosing Safety and Meaningful Antiviral Activity Across First Three PBGENE-HBV Cohorts Designed to Eliminate Source of Hepatitis B Virus Current Standard of Care: Nucleoside Analogs (NUC) and Therapies i
Slide 8: Functional Cure Rates: Current Modalities vs PBGENE-HBV
≥30% Functional Cure Rate Set By HBV Experts has Remained Elusive PBGENE-HBV has opportunity to be clinically meaningful by increasing cure rate Drive Complete Cures Current Approved Drug Modalities or in Late-stage Development By Eliminating cccDNA show single-digit functional cure rates Average Fu
Slide 9: HBV Cure Requires a Novel Approach Targeting the Viral Replication Source
HBV Cure Requires a Novel Approach Targeting the Viral Replication Source Eliminating cccDNA has a Clear Biologic Rationale for Cure PBGENE HBV "The ideal therapeutic strategy for curative approaches includes reduction or elimination of the whole cccDNA pool.“ PBGENE-HBV is uniquely designed to seek
Slide 10: New Rules for a New Modality: Direct Viral Elimination of Hepatitis B
New Rules for a New Modality: Resetting the Ground Rules for Direct Viral Elimination of Hepatitis B - the ONLY Path to Complete Cure PBGENE-HBV First and Only Clinical Stage Program Demonstrating Promising Data with Path Towards Stopping NUCs to Test for Cure Reducing HBsAg is Not Enough: 〉 PBGENE-
Slide 11: Phase 1/2a Study Design
Phase 1/2a Study Design Potential for rapid evaluation of safety and efficacy of PBGENE-HBV Part 1: Multiple Ascending Dose Escalation Part 2: Dose Expansion Finite Treatment: Patient receives up to 3 dose administrations* Advance optimized dose and schedule to eliminate cccDNA and drive cure Additi
Slide 12: PBGENE-HBV was Well Tolerated with Repeat Dosing Across All Dose Levels
PBGENE-HBV was Well Tolerated with Repeat Dosing Across All Dose Levels Adverse events were predictable and manageable Number of patients experiencing 0.2 mg/kg 0.4 mg/kg 0.8 mg/kg treatment-related: n=3 n=3 n=3 Any Grade 1 AEs 2 3 3 No DLTs have been observed Chills 2 across all 22 doses given2 Fev
Slide 13: PBGENE-HBV: Well Tolerated Across All Three Cohorts
PBGENE-HBV: Well Tolerated Across All Three Cohorts 〉PBGENE-HBV has been well tolerated with repeat doses spanning dose levels of 0.2 mg/kg, 0.4 mg/kg and 0.8 mg/kg (n=22 doses administered) 〉Adverse events were predictable, manageable, and quickly resolved across broad range of global sites 〉Transa
Slide 14: Clear Antiviral Activity Alongside Durable Responses
Clear Antiviral Activity Alongside Durable Responses Dose Dependent Effects Established Through Increasing Dose Levels Cohort 1 | 0.2 mg/kg Cohort 2 | 0.4 mg/kg Cohort 3 | 0.8 mg/kg Activity in 3 of 3 patients Activity in 3 of 3 patients Activity in 3 of 3 patients Durable response in 1 of 3 patient
Slide 15: Measuring the Viral Source with Biopsy
Measuring the Viral Source with Biopsy Participant 5 underwent pre and post treatment biopsy Patient 5 〉 Molecular biopsy data in Patient 5 was taken 3500 to a 44% decline in HBsAg X% after 2 dose administrations and corresponds 3000 editing in 44% 44% 〉 After the third dose administration, PatientD
Slide 16: Potential Path to Stopping NUCs and Testing For Cure
With Dose Dependent and Durable Antiviral Effects, PBGENE-HBV is on Potential Path to Stopping NUCs and Testing For Cure Repeat dosing designed to drive cumulative Only mechanism targeting cccDNA elimination in antiviral effects and cure development with potential for complete cure 700 Dose #1 600 W
Slide 17: Next Steps: Progression into Part 2 Expansion and Beyond
Next Steps: Progression into Part 2 Expansion and Beyond Complete Dosing Stop NUCs, Expand for Cohort 3 Test for Cure to Part 2 All 3 doses expected to Will consider stopping NUCs Expect to dose up to 45 complete in Q1 2026 after observing two sustained, patients between Part 1 and low HBsAg measure
Slide 18: What Does Success for ELIMINATE-B Look Like?
What Does Success for ELIMINATE-B Look Like? Two FDA Regulatory Pathways Support Advancement of Therapies in Hepatitis B Current therapies in development have not been able to directly target cccDNA and hence the path towards approval has focused on functional cure GUIDANCE DOCUMENT through HBsAg lo
Slide 19: PBGENE-DMD
PBGENE-DMD Precision’s muscle program utilizing novel gene excision approach for majority of patients with Duchenne Muscular Dystrophy (DMD) 18
Slide 20: PBGENE-DMD Designed to Provide Durable Functional Improvement for 60% of Patients with DMD
PBGENE-DMD Designed to Provide Durable Functional Improvement for 60% of Patients with DMD PBGENE-DMD: A single AAV encodes two ARCUS proteins designed to permanently edit a patient’s own DNA sequence, resulting in naturally-expressed, functional dystrophin Up to 60% ARCUS 1 ARCUS 2 of patients have
Slide 21: Near Full Length Dystrophin Protein Has Known Function in Del45-55 Genotype
Near Full Length Dystrophin Protein has Known Function in Individuals with Dystrophin Del45-55 Genotype Lifespan: Lifespan: • Early death in late teens or 20s • Can live into 60-70s1-3 Clinical Presentation: Clinical Presentation: • Progressive muscle weakness leading • Asymptomatic or mild to loss
Slide 22: PBGENE-DMD Resulted in Increased Dystrophin Protein Levels Over Time
PBGENE-DMD Resulted in Increased Dystrophin Protein Levels Over Time, Exceeding Expected Therapeutic Threshold Heart Calf Quadricep 20 30 25 25 20 Dystrophin Restoration (%) Dystrophin Restoration (%) Dystrophin Restoration (%) 15 20 15 10 15 10 10 5 5 5 0 0 0 Treated disease mice Treated disease mi
Slide 23: PBGENE-DMD Significantly Improved Muscle Function and Demonstrated Potential for Long-Term Durability
PBGENE-DMD Significantly Improved Muscle Function and Demonstrated Potential for Long-Term Durability Untreated Untreated PBGENE-DMD PBGENE-DMD Diseased Healthy (1x1014 vg/kg) (3x1013 vg/kg) 200% Normalized Force/BW 150% to Untreated Disease 100% 50% 0% 〉Improved muscle function observed from 3 to 6
Slide 24: Phase I/II/III Study Designed for Safety and Speed
Phase I/II/III Study Designed for Safety and Speed Phase I/II – Establish Safety and Efficacy Planned Pivotal Trial Single-Dose Level Design Final dose to be aligned with regulators (e.g., 1e14 vg/kg) Plan: 〉Treat a total of 35 to 40 〉Enroll 5-8 ambulatory patients across multiple Move to patients a
Slide 25: Upcoming 2026 Milestones and Outlook
Upcoming 2026 Milestones and Outlook • PBGENE-HBV - Additional data expected to be shared at hepatitis-focused medical conferences in 2026 - Exploring multiple levers to optimize therapeutic index - Continuing Cohort 3 AND Cohorts 4 & 5 initiated in parallel to evaluate administration every 4 weeks
Slide 26: Appendix
PRECISION BIOSCIENCES Appendix my 25
Slide 27: The ARCUS Cut is Uniquely Designed to Drive Defined Outcomes
The ARCUS Cut is Uniquely Designed to Drive Defined Outcomes ARCUS cut leads to HDR or “Perfect” Re-ligation Cas9 C C G TAT G C A AT TA G C TA G G T C G Blunt cut G G C ATA C G T TA AT C G AT C C A G C induces NHEJ The ARCUS Cut TALEN/ZFN Generates a DNA replication direction C C G TAT G C A AT TA G
Slide 28: Size Matters for Where You Can Deliver
Size Matters for Where You Can Deliver ARCUS can use different delivery vehicles to target diverse tissue types ARCUS LNP AAV Liver Eye Muscle CNS Other 27
Slide 29: Size Matters for What You Can Deliver
ARCUS 1500 bp SaCas9 4200 bp AAV Genome Capacity ~4700 bp Size Matters for ARCUS Cas12a 4900 bp What You Can Deliver: Small ARCUS Size Allows SpCas9 Two Nucleases in One AAV 5100 bp ARCUS for Gene Excision as in our PBGENE-DMD program Base Editor (ABEmax) 5800 bp – 6500 bp Prime Editor (PEmax) 7200
Slide 30: ARCUS for the More Sophisticated Gene Edit
ARCUS for the More Sophisticated Gene Edit Designed by nature for a multitude of applications versus other gene editing modalities Replace Remove defective and insert functional gene Insertion Insert gene to add function Degree of Difficulty ARCUS Remove portion of genome, high Capability To Perform
Slide 31: Current Therapeutic Strategies Rarely Achieve Functional Cure Because They Leave cccDNA Present
Current Therapeutic Strategies Rarely Achieve Functional Cure Because They Leave cccDNA Present cccDNA Integrated HBV DNA Hepatocytes Bloodstream D Current therapies in HBsAg mRNAs pgRNA C development target HBV RNA downstream Even combining antivirals and A B immune modulators, functional component
Slide 32: Proof of Mechanism: Evidence of PBGENE-HBV Activity on Viral DNA
Hot off The Press - Proof of Mechanism: Evidence of PBGENE-HBV Activity on Viral DNA Preclinical NHP Viral DNA Editing Clinical Biopsy Data (Two Admins at 0.5 mg/kg) (Two Admins at 0.4 mg/kg) Inactivation with indels % Viral DNA Editing 100 28% 80 in remaining DNA 60 40 Elimination Elimination of vi
Slide 33: Precision BioSciences Leadership Team Brings Strategic and Operational Experience
Precision BioSciences Leadership Team Brings Strategic and Operational Experience Michael Amoroso Jeff Smith, Ph.D. Cassie Gorsuch, Ph.D. Alex Kelly Cindy Atwell Since Oct 2021 Since March 2006 Since June 2016 Since Oct 2020 Since April 2019 President & Chief Research Officer, Chief Scientific Offic
Precision BioSciences — Investor Presentation (January 2026) on 6ix